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Background—Left atrium (LA) enlargement is common in organic mitral regurgitation (MR) and is an emerging
prognostic indicator. However, outcome implications of LA enlargement have not been analyzed in the context of
routine clinical practice and in a multicenter study.
Methods and Results—The Mitral Regurgitation International DAtabase (MIDA) registry enrolls patients with organic MR
due to flail leaflets, diagnosed in routine clinical practice, in 5 US and European centers. We investigated the relation
between LA diameter and mortality under medical treatment and after mitral surgery in 788 patients in sinus rhythm
(6412 years; median LA, 48 [43 to 52] mm). LA diameter was independently associated with survival after diagnosis
(hazard ratio, 1.08 [1.04 to 1.12] per 1 mm increment). Compared with patients with LA 55 mm, those with LA
55 mm had lower 8-year overall survival (P0.001). LA 55 mm independently predicted overall mortality (hazard
ratio, 3.67 [1.95 to 6.88]) and cardiac mortality (hazard ratio, 3.74 [1.72 to 8.13]) under medical treatment. The
association of LA 55 mm and mortality was consistent in subgroups. Similar excess mortality associated with LA
55 mm was observed in asymptomatic and symptomatic patients (P for interaction, 0.77). In patients who underwent
mitral surgery, LA 55 mm had no impact on postoperative outcome (P0.20). Mitral surgery was associated with
greater survival benefit in patients with LA 55 mm compared with LA 55 mm (P for interaction, 0.008).
Conclusions—In MR caused by flail leaflets, LA diameter 55 mm is associated with increased mortality under medical
treatment, independent of the presence of symptoms or left ventricular dysfunction. (Circ Cardiovasc Imaging. 2011;4:473-481.)
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Mitral regurgitation (MR) is a progressive disease asso-ciated with high morbidity and mortality under conser-
vative treatment.1,2 Guidelines3,4 recommend mitral surgery
in patients with MR and overt symptoms, left ventricular
(LV) dysfunction, pulmonary hypertension, or atrial fibrilla-
tion (AF) because these patients are at high risk of death and
cardiac events under medical treatment.5–7 However, patients
with “guideline surgical indications” may incur excess mor-
tality even after successful surgery,5–7 and therefore, addi-
tional markers of risk are needed to better identify high-risk
groups and define the optimal timing of surgery.
Clinical Perspective on p 481
Left atrium (LA) enlargement secondary to volume over-
load is common in chronic organic MR, reflecting both the
severity and the duration of MR.8 In chronic organic MR, LA
enlargement is the expression of the regurgitated volume,
the intrinsic compliance of the LA, and the associated LV
function impairment.9,10 In contrast with LV dimensions
and LV ejection fraction (EF), LA size is affected to a
lesser degree by acute changes in preload or afterload and
it therefore reflects the average effect of LA pressure over
time.11 Previous reports have shown that in the general
population LA enlargement is predictive of death,12–14
incident heart failure,15 AF16 and stroke.13 Moreover, there
is a close relation between LA enlargement and mortality
in high-risk groups such as dilated cardiomyopathy,17
myocardial infarction,18 and after aortic or mitral10 valve
surgery.
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In patients with organic MR, single-center studies sug-
gested that LA size is a marker for subsequent AF.19–21 In
regard to survival under medical treatment, pilot data suggest
that LA enlargement measured by LA volume may be a
useful predictor.22 However, LA diameter23,24 is currently of
more widespread use than LA volume. Furthermore, gener-
alizability of LA enlargement as a marker of MR outcome
requires testing in large numbers of patients, diagnosed in
routine practice and in a multicenter setting. The Mitral
Regurgitation International DAtabase (MIDA) registry is an
international database gathered to analyze the outcome of MR
due to flail leaflets, and offers a unique opportunity to address
this issue. Therefore, we sought to establish whether this
simple measure of LA enlargement is predictive of mortality
under medical treatment and after mitral surgery in a large
cohort of patients with organic MR due to flail leaflets2,7 in
sinus rhythm.
Methods
Study Design
The MIDA registry was previously described.2,7 Briefly, we merged
the consecutive experience with MR due to flail leaflets of 5 centers,
4 tertiary centers in Europe and 1 center in the United States. The
process of forming each center dataset involved retrospective iden-
tification of consecutive patients diagnosed with MR due to flail
leaflets since inception of echocardiographic database. We obtained
institutional review board authorizations prior to conducting the
study. The study was conducted in accordance with institutional
policies, national legal requirements, and the revised Helsinki
Declaration.
Patients were screened for the study if they had degenerative MR
with flail leaflet diagnosed by 2D echocardiography.2 A comorbidity
index summating the patient’s comorbidities was calculated.25 The
registry currently includes 1158 patients. LA diameter was available
in 1004 patients (87%). In 154 patients (13%), LA diameter was not
measurable, due in general to morphotype. Given the independent
effect of AF on LA enlargement, for this analysis we considered only
patients in sinus rhythm at baseline (n788).
Echocardiography
Transthoracic echocardiograms were performed within routine clin-
ical practice, using standard methods.2 LA diameter was measured in
M-mode at end-systole in the parasternal long-axis view, according
to the method proposed by the American Society of Echocardiogra-
phy.26 When M-mode measurement was not possible (oblique
incidence), 2D measurement was performed. Severity of MR was
assessed semiquantitatively on a scale from 1 to 4 by Doppler
echocardiography.2 Diagnosis of flail leaflet was based on the failure
of leaflet cooptation, with rapid systolic movement of the involved
leaflet tip in the left atrium.2,27
Follow-Up
Follow-up collection was achieved for 760 patients (96%) up to 2006
or death. The main end point was overall survival after diagnosis
under medical treatment. Other end points were cardiac mortality,
overall survival encompassing medical and surgical treatment and
postoperative survival in patients who underwent surgery. During
follow-up, patients were monitored by their personal physicians.
Events were ascertained by clinical interviews and/or by telephone
calls to physicians, patients, and (if necessary) next of kin. Autopsy
records and death certificates were consulted for attribution of causes
of death.2,7
Statistical Analysis
Continuous variables were expressed as mean value 1 SD, and
categorical variables were summarized as frequency percentages.
The relationship between continuous baseline variables and LA
categories was explored using 1-way ANOVA or the Kruskal-Wallis
test, as appropriate. Pearson 2 statistic or Fisher exact test were used
to examine the association between categories of LA diameter and
baseline categorical variables. The significance between the lowest
LA category (LA50 mm) and the others was examined if there was
a significant difference across categories. Probability values were not
adjusted for multiple comparisons and therefore are provided only
for descriptive purposes.
For the analysis of outcome under conservative treatment, data
were censored at the time of cardiac surgery, if eventually per-
formed. The entire follow-up was used to analyze outcomes under
conservative and surgical treatment. The effect of mitral surgery on
outcome was analyzed as a time-dependent covariate using the entire
follow-up. The survival time of patients lost to follow-up was
censored at the date of last contact. The best prognostic LA diameter
cutoff value for overall mortality was defined using receiver oper-
ating characteristic curve analysis according to the best sensitivity,
specificity, and likelihood ratio. Overall mortality rates were esti-
mated according to the Kaplan-Meier method and compared with a
2-sided log-rank test. Univariate and multivariable analyses of time
to events were performed using Cox proportional hazards models
with LA diameter as the predictor variable in continuous and
categorical format. We did not use model-building techniques and
entered in the models covariates considered of potential prognostic
impact on an epidemiological basis. These covariates were: comor-
bidity index (including age), sex, symptoms, EF, and left ventricular
end-systolic diameter (LVESD). We analyzed cardiac death in a Cox
proportional hazards multivariable model while patients who died of
noncardiac causes were censored (as nonevents) at the time of death.
Hazard ratios (HR) and 95% confidence intervals (CI) were esti-
mated for cardiac death. Plots of cumulative hazard functions were
used to graphically display death of cardiac causes. The proportional
hazards assumption was confirmed using statistics and graphs based
on the Schoenfeld residuals. Penalized smoothing splines (P-splines)
were used to illustrate the association of LA diameter as a continuous
variable and the risk of overall mortality under medical treatment.7
We conducted subgroup analyses to determine the homogeneity of
the association of LA diameter and mortality. First, we estimated the
effect of LA diameter on mortality in each subgroup, using a Cox
univariate model, and then we formally tested for first-order inter-
actions in Cox models entering interaction terms, separately for each
subgroup. A significance level of 0.05 was assumed for all tests. All
probability values are results of 2-tailed tests. Data were analyzed
with SPSS 13.0 (SPSS Inc, Chicago, IL) and S-Plus 8.0 (Insightful
Inc, Seattle, WA). Receiver operating characteristic curve analysis
was performed using MedCalc for Windows version 11.3 (MedCalc
Software, Mariakerke, Belgium). The authors had full access to the
data and take responsibility for its integrity. All authors have read
and agree to the manuscript as written.
Results
Baseline Characteristics
The baseline characteristics of the 788 patients with organic
MR due to flail leaflets in sinus rhythm, overall and stratified
by LA diameter 50 mm, 50 to 54 mm, and 55 mm are
presented in Table 1. Ninety-one percent of patients had
grade 3 to 4 MR by Doppler echocardiography. Mean LA
diameter was 47.78.0 mm (median, 48 mm; interquartile
range, 43 to 52 mm). Compared with patients with LA
50 mm, those with LA 50 to 54 mm and LA 55 mm were
more often male and had more severe symptoms at baseline
but similar comorbidity index (Table 1). Patients with greater
LA dilation had larger ventricular dimensions, lower EF, and
higher systolic pulmonary artery pressure (Table 1).
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Outcome With Medical Treatment
All-Cause Mortality
Seventy-two deaths were recorded during follow-up under
conservative treatment. Eight-year survival was similar in
patients with LA 50 mm and patients with LA 50 to 54 mm
(P0.27; Figure 1). Patients with LA 55 to 59 mm displayed
lower 8-year survival compared with patients with LA
50 mm (P0.001) and patients with LA 50 to 54 mm
(P0.013, Figure 1). LA enlargement 60 mm was not
associated with poorer 8-year survival compared with LA 55
to 59 mm (P0.70). Eight-year survival rate was higher for
patients with LA 55 mm compared with patients with LA
55 mm (Figure 2A).
On multivariable analysis, after adjustment for comorbidity
index, sex, symptoms, EF, and LVESD, LA diameter was
independently associated with overall mortality (Table 2).
The character of the relationship between LA diameter and
the risk of overall mortality under conservative treatment was
estimated using spline functions for LA diameter (Figure 3).
On multivariable analysis, there was no increase in mortality
risk with increasing LA diameter when it remained 55 mm
(adjusted HR, 1.05 [0.98 to 1.11] per 1-mm LA diameter
increment; P0.18). With LA 55 mm, there was a signif-
icant increase in mortality risk with increasing LA diameter
(adjusted HR, 1.03 [1.01 to 1.07] per 1-mm LA increment;
P0.04). Compared with patients with LA 50 mm, those
with LA 50 to 54 mm did not display excess mortality risk
(adjusted HR, 1.39 [0.63 to 3.09]; P0.42). The risk of
all-cause mortality under medical treatment was significantly
increased for patients with LA 55 to 59 mm and patients with
LA 60 mm (adjusted HR, 2.91 [1.31 to 6.46]; P0.009 for
LA 55 to 59 mm versus LA 50 mm, and, respectively,
Table 1. Baseline Characteristics of the Study Population by Left Atrium Diameter
Variable
All Patients
(n788)
LA Diameter
P
50 mm
(n477)
50 to 54 mm
(n172)
55 mm
(n139)
Age, y 64.112.5 63.613.1 65.511.2 64.211.9 0.23
Male sex, % (n) 69.3% (546) 66.5% (317) 69.2% (119) 79.1% (110)* 0.017
Overt symptoms, % (n) 27.7% (218) 24.9% (119) 29.7% (51) 34.5% (48)* 0.04
NYHA class, % (n)
I 42.0% (331) 45.3% (216) 39.5% (68) 33.8% (47)* 0.08
II 30.3% (239) 29.8% (142) 30.8% (53) 31.7% (44)
III 21.0% (166) 18.2% (87) 22.1% (38) 29.5% (41)
IV 6.6% (52) 6.7% (32) 7.6% (13) 5.0% (7)
Medical history
Coronary artery disease, % (n) 7.1% (56) 6.7% (32) 5.8% (10) 10.1% (14) 0.30
Hypertension, % (n) 34.2% (269) 35.1% (167) 33.3% (57) 32.4% (45) 0.81
Diabetes mellitus, % (n) 5.3% (42) 4.8% (23) 6.4% (11) 5.8% (8) 0.72
Dyslipidemia, % (n) 30.9% (242) 30.6% (145) 33.9% (58) 28.5% (39) 0.57
Peripheral vascular disease, % (n) 5.3% (42) 5.9% (28) 3.5% (6) 5.8% (8) 0.47
Chronic obstructive pulmonary disease, % (n) 8.1% (64) 9.2% (44) 6.4% (11) 6.5% (9) 0.37
Cerebrovascular disease, % (n) 2.5% (20) 2.7% (13) 2.9% (5) 1.4% (2) 0.66
Infective endocarditis, % (n) 9.3% (73) 8.8% (42) 10.5% (18) 9.4% (13) 0.81
Charlson Comorbidity Index 2.91.8 2.81.8 3.01.8 3.11.9 0.10
Echocardiographic data
LVEDD, mm 59.37.2 57.36.3 60.57.3† 64.77.0† 0.001
LVESD, mm‡ 35.56.7 34.36.1 35.86.6* 39.77.2† 0.001
Ejection fraction, % 65.99.2 66.68.8 65.99.8 63.99.9* 0.011
Systolic pulmonary artery pressure, mm Hg§ 42.014.4 39.512.9 41.913.3 49.217.3† 0.001
Medical therapy, % (n)
Angiotensin-converting enzyme inhibitors 47.3% (371) 46.2% (220) 45.9% (78) 52.5% (73) 0.39
-Blockers 19.7% (155) 20.6% (98) 17.1% (29) 20.1% (28) 0.61
Diuretics 37.0% (290) 34.0% (161) 38.2% (65) 46.0% (64)* 0.032
LA indicates left atrium; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; and NYHA, New York Heart
Association.
*P0.05, individual category versus LA 50 mm.
†P0.001, individual category versus LA 50 mm.
‡LVESD missing in 72 patients.
§Systolic pulmonary artery pressure missing in 415 patients.
Charlson Comorbidity Index includes age.
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adjusted HR, 6.94 [2.93 to 16.5]; P0.001 for LA 60 mm
versus LA 50 mm).
Death of Cardiac Causes
During conservative follow-up, 49 deaths of cardiac causes
occurred. Causes of death were LV dysfunction (n31,
63.2%), sudden death (n12, 24.5%), thromboembolism
(n2, 4.1%), myocardial infarction (n2, 4.1%), infective
endocarditis (n1, 2.0%), and aortic aneurysm rupture (n1,
2.0%). After adjustment for comorbidity index, sex, symp-
toms, EF, and LVESD, LA diameter was independently
predictive of death of cardiac causes (Table 2, Figure 4A).
There was a significant increase in cardiac mortality with
increasing LA when it was55 mm (HR, 1.04 [1.02 to 1.08] per
1-mm LA diameter increment; P0.03) but not when it re-
mained 55 mm (HR, 1.07 [0.98 to 1.18] per 1-mm LA
diameter increment; P0.10). Compared with patients with LA
50 mm, the risk of death of cardiac causes increased for
patients with LA 55 to 59 mm and patients with LA 60 mm
(adjusted HR, 3.09 [1.15 to 8.36], P0.026 for LA 55 to 59 mm
versus LA 50 mm, and adjusted HR, 7.31 [2.51 to 21.4];
P0.001 for LA 60 mm versus LA 50 mm). Outcome was
comparable for patients with LA50 mm and patients with LA
50 to 54 mm (adjusted HR, 1.59 [0.58 to 4.33], P0.36).
Figure 1. Overall survival by left atrium (LA) diame-
ter (50 mm; 50 to 54 mm; 55 to 59 mm;
60 mm) under conservative treatment.
Figure 2. Overall survival according to left atrium (LA) diameter (55 and 55 mm) under conservative treatment (A) and with medical
and surgical treatment (B). A, Analysis of survival under conservative treatment took into account the overall follow-up for patients who
had only medical therapy and preoperative follow-up for patients who were operated on (censored at surgery). B, Analysis of survival
with medical and surgical treatment took into account the entire follow-up.
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Subgroup Analysis
The association of LA 55 mm and all-cause mortality was
consistent in subgroups of patients with MR (Figure 5). There
were no significant interactions between LA 55 mm and
any of the subgroups.
Patients in New York Heart Association (NYHA) class I at
baseline with LA 55 mm had better outcome compared
with the group with LA 55 mm (8-year overall survival:
834% versus 5715%, P0.032). After adjustment for
covariates, LA 55 mm was independently predictive of
overall mortality (adjusted HR, 2.40 [1.03 to 5.63]; P0.044)
and death of cardiac causes (adjusted HR, 3.42 [1.09 to 10.7];
P0.035). The effect of LA 55 mm on overall mortality
was similar in asymptomatic and symptomatic MR patients at
baseline (P for interaction, 0.77).
In patients with EF 60% at baseline, 8-year survival rate
was significantly higher for patients with LA 55 mm
compared with patients with LA 55 mm (7110% versus
87%; P0.001). The risk of cardiac death was greater with
LA 55 mm compared with LA 55 mm (HR, 4.07 [1.46 to
11.4]; P0.007). Patients with normal EF and LA 55 mm
displayed better 8-year overall survival compared with the
group with LA 55 mm (784% versus 6312%;
P0.005). In this subgroup, patients with LA 55 mm had
also increased risk of cardiac death compared with LA
55 mm (HR, 3.62 [1.71 to 7.67]; P0.001).
The prognostic value of baseline LA diameter 55 mm
was unaltered after excluding patients presenting with symp-
toms (NYHA class II-IV), reduced EF (60%) and left
ventricular dilation (LVESD 40 mm). In this subgroup of
222 patients without surgical indication at baseline, baseline
LA 55 mm was associated with lower overall survival
(5520% versus 884%; P0.034) and greater risk of
cardiac death (HR, 6.32[1.57 to 25.5]; P0.01).
Outcome With Medical and Surgical Treatment
Mean duration of follow-up with medical and surgical treat-
ment was 6.23.9 years (median, 5.9; interquartile range, 2.8
to 9.2 years). In 29% of patients (n225), treatment was
solely medical, whereas 71% of patients (n563) underwent
mitral valve surgery. Mean time interval between baseline
echocardiography and mitral surgery was 1.32.3 years
(median, 0.2; interquartile range, 0.07 to 1.2 years). Valve
repair was performed in 449 patients (80%) and valve
replacement in 114 patients (20%).
During follow-up with medical and surgical treatment, 155
deaths were recorded. Eight-year survival rate was higher for
patients with LA 55 mm compared with patients with LA
55 mm (Figure 2B). LA diameter was independently
predictive of mortality (with medical and surgical treatment)
in both continuous and categorical format (Table 2). Death of
cardiac causes was recorded in 90 cases. On multivariable
analysis, LA 55 mm was also predictive of cardiac death
(Table 2 and Figure 4B).
Postoperative Outcome
In patients who underwent mitral surgery (n563), mean
postoperative follow-up was 4.14.0 years (median, 3.2;
Figure 3. Relationship between left atrium (LA) diameter and the
risk of overall mortality under conservative treatment. Hazard
ratio (solid line) and 95% confidence intervals are estimated in a
Cox model, with LA diameter represented as a spline function
and adjusted for comorbidity index, sex, symptoms, and ejec-
tion fraction. The horizontal line corresponds to a hazard ratio of
1.00.
Table 2. Relative Risk of Overall Death and Death of Cardiac Causes Associated With Left Atrium Diameter
Medical Treatment Medical and Surgical Treatment*
Overall Death Cardiac Death Overall Death Cardiac Death
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% Cl) P
LA diameter 55 mm
Model 1 3.22 (1.92–5.43) 0.001 3.60 (1.92–6.76) 0.001 1.91 (1.33–2.74) 0.001 1.89 (1.17–3.05) 0.009
Model 2 2.69 (1.57–4.60) 0.001 2.84 (1.46–5.49) 0.002 1.76 (1.22–2.54) 0.002 1.69 (1.03–2.74) 0.03
Model 3 3.67 (1.95–6.88) 0.001 3.74 (1.72–8.13) 0.001 1.78 (1.19–2.67) 0.005 1.66 (0.96–2.85) 0.06
Per 1-mm increment in LA diameter
Model 1 1.07 (1.04–1.11) 0.001 1.09 (1.05–1.13) 0.001 1.04 (1.02–1.06) 0.001 1.05 (1.02–1.08) 0.001
Model 2 1.06 (1.03–1.09) 0.001 1.08 (1.04–1.12) 0.001 1.03 (1.01–1.05) 0.001 1.04 (1.02–1.07) 0.002
Model 3 1.08 (1.04–1.12) 0.001 1.09 (1.04–1.15) 0.001 1.03 (1.01–1.06) 0.004 1.04 (1.00–1.07) 0.01
CI indicates confidence interval; EF, left ventricular ejection fraction; HR, hazard ratio; LA, left atrium; and LVESD, left ventricular end-systolic diameter.
Model 1: Adjusted for comorbidity index (includes age).
Model 2: Adjusted for comorbidity index, sex, symptoms, and EF.
Model 3: Adjusted for comorbidity index, sex, symptoms, EF and LVESD (missing in 72 patients).
*Analysis of outcome with medical and surgical treatment included the above-mentioned covariates and surgery as time-dependent covariate.
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interquartile range, 0 to 7.1 years). The baseline characteris-
tics of patients who underwent surgery during follow-up and
of patients who were treated medically are presented in Table
3. Compared with surgical patients, patients who were treated
medically were older and had milder symptoms and less
severe markers of volume overload (Table 3). On univariate
analysis, LA diameter was not associated with postoperative
death (HR, 1.14 [0.68 to 1.91] for LA 55 mm versus LA
55 mm; P0.62, and HR, 1.01 [0.97 to 1.03] per 1 mm LA
increment; P0.97) and death of cardiac causes (HR, 0.79
[0.35 to 1.78] for LA 55 mm versus LA 55 mm; P0.57,
and HR, 1.00 [0.96 to 1.04] per 1-mm LA increment;
P0.94). After adjustment for covariates, LA 55 mm was
still not a predictor of postoperative death (adjusted HR, 1.09
[0.63 to 1.88]; P0.77) and death of cardiac causes (adjusted
HR, 0.79 [0.34 to 1.84]; P0.59).
On multivariable analysis, surgery was associated with
improved overall survival (adjusted HR, 0.49 [0.31 to 0.78];
P0.003) and survival free of cardiac death (adjusted HR,
0.37 [0.20 to 0.69]; P0.002). The survival benefit after
surgery was greater in patients with LA 55 mm (adjusted
HR, 0.12 [0.07 to 0.22]; P0.001) compared with patients
with LA 55 mm (adjusted HR, 0.52 [0.31 to 0.85];
P0.009; P for interaction, 0.008).
Discussion
In this large international cohort of patients with MR due to
flail leaflets in sinus rhythm, LA diameter was a strong
predictor of outcome under medical treatment. The effect of
LA diameter on outcome was powerful and remained valid
after adjustment for factors known as major determinants of
prognosis such as age, comorbidity, symptoms, and LV
function. Thus, LA diameter 55 mm was associated with
more than 3-fold increase in the risk of all-cause mortality
and risk of cardiac death under medical treatment. During
follow-up with conservative treatment, the mortality risk
associated with LA 55 mm was not significantly different
in patients with LV dysfunction and patients with normal EF
at baseline. Moreover, asymptomatic patients with LA
55 mm incurred excess mortality under medical treatment
Figure 4. Cumulative hazard functions plots for cardiac death in patients with left atrium (LA) diameter 55 mm and 55 mm under
conservative treatment (A) and with medical and surgical treatment (B). Explanatory note: See Figure 2.
Figure 5. Hazard ratios and 95% confidence
intervals for overall mortality associated with
left atrium diameter 55 mm in subgroups of
patients under conservative treatment. CI indi-
cates confidence interval; EF, left ventricular
ejection fraction; HR, hazard ratio; LVESD, left
ventricular end-systolic diameter; and NYHA,
New York Heart Association.
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compared with patients with LA 55 mm. Although LA
55 mm was a potent marker of risk under conservative
treatment, it did not significantly influence postoperative
outcome of patients who underwent surgery and mitral
surgery was associated with marked mortality reduction,
especially in patients with LA 55 mm.
LA enlargement and remodeling in various cardiac condi-
tions are mainly the consequence of volume overload, as in
valvular regurgitation8 or pressure overload reflecting in-
creased LV filling pressures.28,29 In chronic organic MR, LA
enlargement is the response to the regurgitated volume,
reflecting both the severity and the duration of MR.8 How-
ever, LA size may be influenced by the intrinsic compliance
of the LA and by the associated LV diastolic impairment.8–10
In contrast with LV dimensions and EF, LA size is affected to
a lesser degree by acute changes in preload or afterload and
it therefore reflects the average effect of LA pressure over
time.11 Chronically elevated LA pressures lead to morpho-
logical abnormalities in the LA wall8 and translate into
increased neurohormonal activation and elevated pulmonary
pressures.21 In the present study, patients with increased LA
diameter experienced more severe symptoms and had signif-
icant LV dilation, lower EF, and increased pulmonary pres-
sures. Thus, LA enlargement in organic MR appears to be a
marker of more advanced disease.
Numerous reports demonstrated that in the general popu-
lation, LA enlargement is predictive of death,12–14 incident
heart failure,15 AF,16 and stroke.13 Moreover, in high-risk
groups such as dilated cardiomyopathy17 and myocardial
infarction,18 LA enlargement represents a factor associated
with increased risk of death. In organic MR there are limited
data on the prognostic implications of LA enlarge-
ment.10,19,21,22,27 Thus, LA enlargement has been shown to
predict the occurrence of AF19–21 and heart failure.27 In a
study of 176 patients with symptomatic chronic MR who
underwent mitral valve replacement, Reed et al10 reported LA
size index, calculated by multiplying the maximal transverse
and longitudinal LA dimensions in the apical 4-chamber view
as an independent predictor of cardiac-related mortality after
surgery. Messika-Zeitoun et al21 demonstrated an indepen-
dent association between LA volume and a combined end
point of death or mitral surgery in patients with organic MR
in sinus rhythm. In a recent single-center pilot study22
including patients with organic MR of different etiologies,
patients with indexed LA volume 60 mL/m2 incurred
excess mortality. Nevertheless, LA diameter is an easily
measurable parameter of LA enlargement, currently of more
widespread use than LA volume. Moreover, LA diameter is
always recorded in clinical practice. The current study dem-
onstrates that in patients with chronic organic MR under
medical treatment, LA diameter is associated with excess
all-cause mortality and cardiac mortality with a risk of death
increasing progressively after the threshold of 55 mm. The
pejorative effect of LA 55 mm was constantly observed in
subgroups of MR patients. The judgment on high risk using
LA diameter is therefore simple, feasible in all centers, and is
confirmed by this multicenter study including a homogenous
population of patients with organic MR due to flail leaflets
amenable to valve repair.
The timing of surgery in MR is still debated, especially is
asymptomatic patients1,2,30 and it has been shown that symp-
tomatic patients and patients with overt LV dysfunction incur
excess mortality even after successful surgery.1,2,5,7 Our
results show that LA diameter is a marker of increased risk of
death under conservative treatment and that it does not affect
postoperative survival of patients undergoing surgery. The
evaluation of LA size should therefore be systematically
performed and considered when discussing surgery together
with LV dimensions, EF, and symptoms.
A limitation of the present study was that clinical and
nonechocardiographic data were obtained by review of med-
ical records.2 Our analysis is based strictly on the LA
long-axis dimension, which is not always reflective of LA
Table 3. Comparison Between Patients Who Had an Exclusive
Medical Treatment During Follow-Up and Patients Who
Underwent Surgery
Variable
Patients
Treated
Medically
(n225)
Operated
Patients
(n563) P
Age, y 66.914.6 62.911.4 0.001
Male sex, % (n) 68.0% (153) 69.8% (393) 0.62
Overt symptoms, % (n) 13.8% (31) 33.2% (187) 0.001
NYHA class, % (n)
I 56.9% (128) 36.1% (203) 0.001
II 29.3% (66) 30.7% (173)
III 12.9% (29) 24.3% (137)
IV 0.9% (2) 8.9% (50)
Medical history
Coronary artery disease, % (n) 9.8% (22) 6.0% (34) 0.10
Hypertension, % (n) 33.3% (75) 34.5% (194) 0.74
Diabetes mellitus, % (n) 6.3% (14) 5.0% (28) 0.47
Dyslipidemia, % (n) 25.3% (57) 32.9% (185) 0.045
Peripheral vascular disease, % (n) 7.1% (16) 4.6% (26) 0.23
Chronic obstructive pulmonary
disease, % (n)
8.9% (20) 7.8% (44) 0.61
Cerebrovascular disease, % (n) 3.1% (7) 2.3% (13) 0.51
Infective endocarditis, % (n) 10.7% (24) 8.7% (49) 0.39
Charlson comorbidity index 3.32.1 2.81.7 0.001
Echocardiographic data
LA diameter 45.77.9 48.97.9 0.001
LVEDD, mm 57.16.9 60.27.1 0.001
LVESD, mm 34.56.7 35.96.7 0.01
Ejection fraction, % 66.88.9 63.99.8 0.001
Systolic pulmonary artery
pressure, mm Hg
42.314.3 41.914.5 0.82
Medical therapy, % (n)
Angiotensin-converting
enzyme inhibitors
43.1% (97) 48.7% (274) 0.14
-Blockers 20.9% (47) 19.2% (108) 0.61
Diuretics 38.2% (86) 36.2% (204) 0.62
LA indicates left atrium; LVEDD, left ventricular end-diastolic diameter;
LVESD, left ventricular end-systolic diameter; and NYHA, New York Heart
Association.
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enlargement and does not take into account the 3D geometry
of the LA. Although in MR both LA diameter and LA volume
are individually predictive of AF, LA volume displays higher
predictive power for the occurrence of AF than LA diame-
ter.21 LA volume was not available in the MIDA registry and
therefore we could not ascertain its incremental prognostic
value on survival over that of LA diameter. Because all
patients in this registry had flail leaflet, the full spectrum of
MR severity was not represented. In patients with severe MR
who do not have a flail leaflet, there might be doubt as to
whether MR is truly severe or not. In such patients, LA
enlargement might also be a marker of higher risk and help
decision-making. In the present study, patients were followed
by their individual physicians. It is possible that some patients
did not undergo mitral valve surgery despite having an
indication for surgery during follow-up. Unfortunately, this
information was not available in the MIDA registry. The
number of events in the subgroup of asymptomatic patients
with MR was small and results must be cautiously inter-
preted, in particular with regard to potential implications for
surgery in asymptomatic patients. Finally, the issue of supe-
riority of surgery over medical treatment in severe organic
MR is beyond the scope of this analysis and should be based
on randomized data.
Clinical Implications
This study, based on a large international multicenter data-
base, shows that LA diameter is independently predictive of
survival in patients with chronic organic MR due to flail
leaflets in sinus rhythm under medical treatment. The risk of
all-cause death and death of cardiac causes after diagnosis
increases progressively with LA diameter above the 55-mm
threshold. The association between LA diameter 55 mm
and outcome is independent of the presence of factors such as
symptoms and LV function. Surgery is particularly beneficial
with LA 55 mm and does not imply excess postoperative
mortality. LA diameter represents therefore a simple and
easily obtainable echocardiographic measurement that might
improve risk stratification in chronic organic MR.
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CLINICAL PERSPECTIVE
LA enlargement is common in chronic MR and is emerging as an important prognostic marker. However, the outcome
implications of LA enlargement have not been analyzed in the context of routine clinical practice and in a multicenter
study. The present analysis of the MIDA registry aimed to establish whether LA diameter, a simple measure of LA
enlargement, is predictive of mortality under medical treatment and after mitral surgery in patients with organic MR due
to flail leaflets. The relation between LA diameter and mortality was studied in 788 patients in sinus rhythm followed for
6.23.9 years. LA diameter was independently associated with survival after diagnosis (HR, 1.08 [1.04 to 1.12] per 1-mm
increment). The optimal cutoff value for prediction of mortality identified by receiver operating characteristic curve
analysis was 55 mm. LA diameter 55 mm was associated with more than 3-fold increase in the risk of overall and cardiac
mortality under medical treatment. The association of LA diameter 55 mm and mortality was consistent in subgroups of
patients with MR and similar excess mortality was observed in asymptomatic and symptomatic patients. In patients who
underwent mitral surgery, LA diameter 55 mm had no independent impact on postoperative outcome. Our findings show
that LA diameter is a simple measurement that might improve risk stratification and decision making in chronic organic
MR. LA diameter 55 mm is associated with increased mortality under medical treatment, independent of the presence
of symptoms or left ventricular dysfunction.
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